Omar Khwaja has been appointed chief medical officer of Voyager Therapeutics (NASDAQ: [[ticker:VYGR]]). Khwaja comes to the Cambridge, MA-based gene therapy developer from Roche, where he was most recently global head of neuroscience translational medicine and global head of rare diseases. Voyager’s lead drug, VY-AADC, is in mid-stage studies testing it in advanced Parkinson’s disease.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
